Project Grant R21CA317277
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $401K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $426,828 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded July 20, 2026, with completion targeted for June 30, 2028. The award funds fundamental research investigating the neuro-immune axis in obesity-induced liver cancer progression, specifically examining how disruption of communication between the nervous and immune systems...
- Federal Project Grant Award Summary The University of Texas Health Science Center at Houston received a $388,546 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. The award funds fundamental research investigating the role of chromosome 3q (3q)-amplified genes in non-small cell lung cancer (NSCLC) progression, specifically targeting the Golgi secretory pathway. The research focuses on how two...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $2.88 million Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective August 5, 2025, through July 31, 2029. This award supports the development of etiology-adjusted precision liver cancer risk prediction tools and resources. The project focuses on developing non-invasive biomarkers and risk assessment strategies...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a $621,632 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 17, 2026, with a completion date of May 31, 2031. The award supports research to elucidate the mechanisms underlying disulfidptosis—a previously unexplored form of regulated cell death—and to develop therapeutic strategies targeting this cell death pathway in SLC7A11-high cancers. The...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $680,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports the development of drug-loaded degradable biopolymeric scaffolds designed to augment preoperative liver growth in patients with hepatic tumors. The project addresses critical clinical needs in hepatic resection by creating a sustained-delivery system...
- Federal Grant Award Summary Rockefeller University received a $559,596 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The award supports research to identify limiting mitochondrial metabolites that drive the initiation and progression of primary liver cancers, particularly hepatocellular carcinoma (HCC). The research leverages a proprietary organelle immunopurification technique...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $376,886 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026 through June 30, 2029. The grant funds development of novel small-molecule inhibitors targeting Site-One Protease (S1P) to prevent and treat cancers, particularly Clear Cell Renal Cell Carcinoma and Hepatocellular Carcinoma. S1P is a serine protease...
- Federal Grant Award Summary Virginia Commonwealth University (VCU) received a $634,062 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 5, 2026, through May 31, 2031. The award funds fundamental research investigating atypical sphingolipids in hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality. The research focuses on characterizing a novel enzyme subunit, serine palmitoyltransferase long...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...